X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DISHMAN PHARMA - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DISHMAN PHARMA WYETH LTD/
DISHMAN PHARMA
 
P/E (TTM) x 27.7 25.1 110.5% View Chart
P/BV x 5.3 3.3 159.8% View Chart
Dividend Yield % 1.3 0.7 191.7%  

Financials

 WYETH LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DISHMAN PHARMA
Mar-16
WYETH LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044374 279.0%   
Low Rs818129 634.6%   
Sales per share (Unadj.) Rs298.6197.8 150.9%  
Earnings per share (Unadj.) Rs57.221.2 269.9%  
Cash flow per share (Unadj.) Rs58.434.7 168.2%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.8 229.7%  
Book value per share (Unadj.) Rs249.5179.9 138.7%  
Shares outstanding (eoy) m22.7280.69 28.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.3 245.2%   
Avg P/E ratio x16.311.9 137.1%  
P/CF ratio (eoy) x15.97.2 220.0%  
Price / Book Value ratio x3.71.4 266.8%  
Dividend payout %29.79.4 314.9%   
Avg Mkt Cap Rs m21,15720,306 104.2%   
No. of employees `0000.50.8 59.3%   
Total wages/salary Rs m4005,355 7.5%   
Avg. sales/employee Rs Th13,787.419,252.7 71.6%   
Avg. wages/employee Rs Th813.06,459.5 12.6%   
Avg. net profit/employee Rs Th2,643.32,064.1 128.1%   
INCOME DATA
Net Sales Rs m6,78315,961 42.5%  
Other income Rs m353265 132.9%   
Total revenues Rs m7,13616,226 44.0%   
Gross profit Rs m1,6174,103 39.4%  
Depreciation Rs m271,091 2.4%   
Interest Rs m6944 0.6%   
Profit before tax Rs m1,9382,334 83.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m632624 101.4%   
Profit after tax Rs m1,3011,711 76.0%  
Gross profit margin %23.825.7 92.7%  
Effective tax rate %32.626.7 122.1%   
Net profit margin %19.210.7 178.8%  
BALANCE SHEET DATA
Current assets Rs m6,98411,018 63.4%   
Current liabilities Rs m2,0569,517 21.6%   
Net working cap to sales %72.69.4 772.5%  
Current ratio x3.41.2 293.4%  
Inventory Days Days99110 89.8%  
Debtors Days Days2435 68.7%  
Net fixed assets Rs m24416,304 1.5%   
Share capital Rs m227161 140.8%   
"Free" reserves Rs m5,44112,907 42.2%   
Net worth Rs m5,66814,516 39.0%   
Long term debt Rs m254,189 0.6%   
Total assets Rs m7,90129,805 26.5%  
Interest coverage x353.33.5 10,179.4%   
Debt to equity ratio x00.3 1.5%  
Sales to assets ratio x0.90.5 160.3%   
Return on assets %16.58.9 185.5%  
Return on equity %22.911.8 194.6%  
Return on capital %34.017.5 194.2%  
Exports to sales %0.224.8 0.9%   
Imports to sales %36.33.7 972.8%   
Exports (fob) Rs m153,956 0.4%   
Imports (cif) Rs m2,465596 413.4%   
Fx inflow Rs m154,952 0.3%   
Fx outflow Rs m2,677697 384.2%   
Net fx Rs m-2,6624,255 -62.6%   
CASH FLOW
From Operations Rs m9232,786 33.1%  
From Investments Rs m317-1,529 -20.7%  
From Financial Activity Rs m-481-941 51.1%  
Net Cashflow Rs m759316 239.9%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 3.7 305.4%  
FIIs % 7.2 12.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 22.1 137.6%  
Shareholders   21,978 46,261 47.5%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - TORRENT PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS